Lead Product(s): Tocilizumab
Therapeutic Area: Immunology
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Gedeon Richter Plc.
Deal Size: $19.5 million Upfront Cash: $3.0 million
Deal Type: Agreement April 29, 2020
Richter receives worldwide rights to develop, manufacture and commercialise the biosimilar tocilizumab for the treatment of rheumatoid arthritis.